In general, the telomere length has been proposed to be an independent prognostic factor in CLL, with short telomeres being associated with adverse outcome (63–66, 73–76), the presence of del(11q) and del(17p) (64, 72–75, 77), as well as mutations in ATM and TP53 (72–74, 76–78) both of which serve as critical checkpoint genes activated upon telomere shortening. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.